Showing results (231-240 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|September 24, 2016
Current clinical trials testing the combination of immunotherapy with radiotherapyJosephine Kang, Sandra Demaria, Silvia FormentiJournal for Immunotherapy of Cancer|September 24, 2016
Adjuvants for peptide-based cancer vaccinesHiep Khong, Willem W OverwijkJournal for Immunotherapy of Cancer|September 24, 2016
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockadeKaty K Tsai, Miguel H Pampaloni, Charity Hope, et al.Journal for Immunotherapy of Cancer|June 6, 2018
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054Yiwen Li, Carmine Carpenito, George Wang, et al.Journal for Immunotherapy of Cancer|June 6, 2018
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combinationJun Gong, Thang Q Le, Erminia Massarelli, et al.Journal for Immunotherapy of Cancer|June 7, 2018
Immune oncology, immune responsiveness and the theory of everythingTolga Turan, Deepti Kannan, Maulik Patel, et al.Journal for Immunotherapy of Cancer|July 14, 2018
Isolation of T cell receptors targeting recurrent neoantigens in hematological malignanciesVanessa M Tubb, Deborah S Schrikkema, Nathan P Croft, et al.Journal for Immunotherapy of Cancer|July 4, 2018
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanomaMuhammad Zubair Afzal, Rima R Mercado, Keisuke ShiraiJournal for Immunotherapy of Cancer|April 20, 2019
Treatment of malignant pleural effusions: the case for localized immunotherapyAlbert D Donnenberg, James D Luketich, Rajeev Dhupar, et al.Journal for Immunotherapy of Cancer|November 29, 2016
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptideIoannis F Voutsas, Eleftheria A Anastasopoulou, Panagiotis Tzonis, et al.Pageof 424